Alzheimer’s disease currently affects about 4 million Americans and is the 8th leading cause of death, accounting for about 50,000 deaths per year in the U.S. The chance of having Alzheimer’s disease doubles every 4 to 5 years after the age of sixty. Although the risk at age 60 is low (1%), by the age of 75 this reaches almost 10%, and by age 85 between a third and half of Americans have some form of dementia (of which about 75% are the Alzheimer’s type of dementia). Estimates place the risk at about two-thirds of Americans age 90 and above.
This is particularly disturbing news for all of us, since the average American lifespan has been steadily increasing – most women will live to be over 80, and men now average over 75, which means that more than one in ten of us will develop Alzheimer’s disease in our lifetimes.
Despite the many millions of dollars being spent on Alzheimer’s research, the treatment options remain extremely disappointing. Even with earlier, more sensitive diagnostic tests, no effective therapy to has been shown to halt or reverse the disease. The four FDA-approved drugs on the market for Alzheimer’s disease (Aricept®, Exelon®, Reminyl® and the seldom-prescribed Cognex®), only marginally improve function in less than half of patients.
Posts
